Bio-Rad Laboratories Class A
533 hedge funds and large institutions have $14.3B invested in Bio-Rad Laboratories Class A in 2021 Q4 according to their latest regulatory filings, with 83 funds opening new positions, 184 increasing their positions, 199 reducing their positions, and 43 closing their positions.
93% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 43
5% more funds holding
Funds holding: 507 → 533 (+26)
0% less capital invested
Capital invested by funds: $14.4B → $14.3B (-$51.8M)
8% less repeat investments, than reductions
Existing positions increased: 184 | Existing positions reduced: 199
1.45% less ownership
Funds ownership: 78.53% → 77.08% (-1.4%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
61% less call options, than puts
Call options by funds: $42.3M | Put options by funds: $109M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$38M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$37.7M |
| 3 |
Morgan Stanley
New York
|
+$33.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.6M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$230M |
| 2 |
Millennium Management
New York
|
-$105M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$79.3M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$55.1M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$41.8M |
BIO Hedge Fund Activity: Q4 2021 in Review
533 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2021, worth a combined $14.3B — down 0.36% from $14.4B a quarter earlier.
Buyers outnumbered sellers: 83 funds opened new BIO positions and 43 closed out — a net gain of 40 holders — while 184 added to existing stakes and 199 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $38M. The largest seller was Wells Fargo, cutting an estimated $230M.
- 533 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2021, up from 507 in Q3 2021.
- Funds reported $14.3B of Bio-Rad Laboratories Class A stock for Q4 2021, down 0.36% quarter-over-quarter.
- 83 funds opened new Bio-Rad Laboratories Class A positions in Q4 2021 and 43 closed out, a net change of +40 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q4 2021 was Balyasny Asset Management, an estimated $38M added.
- The largest Bio-Rad Laboratories Class A seller in Q4 2021 was Wells Fargo, an estimated $230M sold.
Based on aggregated 13F filings for Q4 2021.